Earlier Monday, the U.S. FDA approved Bausch + Lomb's (BlCO) eye surgery product, the Teneo Excimer Laser Platform, to conduct a surgical procedure called keratomileusis (LASIK).

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic competition in ...

Papa took over as the new CEO of Bausch & Lomb, and oversaw the $2.5bn acquisition of the dry eye disease therapy XIIDRA and other ophthalmology assets from Swiss Pharma giant Novartis AG (NVS ...

Emergent appoints former Bausch + Lomb CEO to head company February 21, 2024 The U.S. Food and Drug Administration (FDA) on Wednesday warned consumers not to use unapproved eye drops that closely ...

Bausch + Lomb said it authorized management and advisers to explore a potential sale of the eye health company after shares dropped over reports of faltering deal talks with a group of private ...

Elios Vision former chairman and CEO Elliot Friedman said: “Bausch + Lomb’s extensive reach in cataract surgery will introduce ELIOS to a broader range of eye care professionals and help ...

Twenty-one months into his second tenure as CEO of Bausch + Lomb, serial dealmaker Brent Saunders ... The company, which sells contact lenses and eye care products, has issued a statement saying ...